SPRO · Spero Therapeutics, Inc. · Webcasts, Transcripts & Audio
Market Cap
$71.63M
Shares
58.23M
Volume · Oct 5
935.7K
Avg daily vol (3M)
1.2M
Spero Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Spero Therapeutics, Inc. (SPRO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼23.3%
$3.06M
−$22.50M
'21 Q3
21-11-10
▲43.9%
$2.74M
−$29.30M
'21 Q4
22-03-31
▼71.7%
$2.07M
−$32.80M
'22 Q1
22-05-16
▼61.3%
$1.99M
−$28.70M
'22 Q2
22-08-10
▼34.5%
$2.01M
−$11.70M
'22 Q3
22-11-14
▲1628.9%
$47.44M
$26.79M
'22 Q4
23-01-09
▲0%
$2.07M
−$13.30M
'23 Q1
23-05-11
▲36.3%
$2.72M
−$11.90M
'23 Q2
23-08-10
▲1169.8%
$25.47M
−$3.20M
'23 Q3
23-11-13
▲55%
$73.52M
$51.21M
'23 Q4
24-03-13
▲275.4%
$10.20M
−$17.86M
'24 Q2
24-08-05
▼79.5%
$15.04M
−$20.89M
'24 Q4
25-03-27
▲39.1%
$14.19M
−$1.70M
'25 Q2
25-08-12
▲174.5%
$41.30M
$31.52M
'25 Q4
26-03-26
▼95.6%
$258,000
−$7.20M
'26 Q1
26-05-13
LATEST
▼100%
$
−$9.55M
'26 Q2
26-08-12
Conference
Investor event
2026-09-15
Spero Therapeutics, Inc. (SPRO) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-12
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
Confident tone
SP001 / CD40 ligand asset
UTEBZ (tebupenem-pivoxil) FDA approval
Royalty financing and balance sheet
Revenue
$
▼ 100% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Spero Therapeutics, Inc. (SPRO) Q1 2026 Earnings Call
Revenue
$258,000
▼ 95.6% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
Spero Therapeutics, Inc. (SPRO) Q4 2025 Earnings Call
Revenue
$41.30M*
▲ 174.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q2
2025-08-12
Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript
Confident tone
Tebipenem HBr oral carbapenem opportunity
PIVOT-PO Phase III success
GSK partnership and economics
Revenue
$14.19M
▲ 39.1% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call
Revenue
$15.04M*
▼ 79.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2024-08-05
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
Positive tone
SPR720 for NTM-PD
Tebipenem-HBr Phase 3 PIVOT-PO
Endpoint definitions and study design
Revenue
$10.20M
▲ 275.4% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-13
Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript
Positive tone
SPR720 in NTMPD (lead asset)
SPR206 IND clearance and funding
Tebipenem HBr Phase 3 PIVOT-PO
Revenue
$73.52M*
▲ 55% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript
Revenue
$25.47M
▲ 1169.8% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Spero Therapeutics, Inc. (SPRO) Q2 2023 Earnings Call Transcript
Revenue
$2.72M
▲ 36.3% YoY Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Spero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Call Transcript
Revenue
$2.07M
▲ 0% YoY Diluted EPS
$-0.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Spero Therapeutics, Inc. (SPRO) Q4 2022 Earnings Call Transcript
Revenue
$47.44M*
▲ 1628.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Spero Therapeutics, Inc. (SPRO) Q3 2022 Earnings Call Transcript
Revenue
$2.01M
▼ 34.5% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Spero Therapeutics, Inc. (SPRO) Q2 2022 Earnings Call Transcript
Revenue
$1.99M
▼ 61.3% YoY Diluted EPS
$-0.87
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Spero Therapeutics, Inc. (SPRO) Q1 2022 Earnings Call Transcript
Revenue
$2.07M
▼ 71.7% YoY Diluted EPS
$-1.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Spero Therapeutics, Inc. (SPRO) Q4 2021 Earnings Call Transcript
Revenue
$2.74M*
▲ 43.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Spero Therapeutics, Inc. (SPRO) Q3 2021 Earnings Call Transcript
Revenue
$3.06M
▼ 23.3% YoY Diluted EPS
$-0.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Spero Therapeutics, Inc. (SPRO) Q2 2021 Earnings Call Transcript
Revenue
$5.15M
▲ 198.1% YoY Diluted EPS
$-0.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Spero Therapeutics, Inc. (SPRO) Q1 2021 Earnings Call Transcript
Revenue
$7.30M
▲ 329.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Spero Therapeutics, Inc. (SPRO) Q4 2020 Earnings Call Transcript
Revenue
$1.91M*
▲ 174% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Spero Therapeutics, Inc. (SPRO) Q3 2020 Earnings Call Transcript
Revenue
$4.00M
▼ 14% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Spero Therapeutics, Inc. (SPRO) Q2 2020 Earnings Call Transcript
Revenue
$1.73M
▼ 19.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-08
Spero Therapeutics, Inc. (SPRO) Q1 2020 Earnings Call Transcript
Revenue
$1.70M
▼ 78% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–23 of 23 webcasts